Explain this page
Arphra AIPlain-English read on Biogen Inc.’s valuation06-10today
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB6h
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB6h
- Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline5d
- Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout5d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$690.17
+250.00% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
9bull3bear
±5% threshold
Analyst PT consensus: $211.42 (+7.22%)
Candlestick · 1Y
Open in chart workstation →BIIB
196.58+55.63%H 205.97L 121.05MA50 190.48MA200 174.70Avg vol 1.5M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.26% | -1.51% | +1.77% | +7.38% | +12.80% | +12.05% | +58.06% | -30.69% | -46.98% | -17.36% | +6210.08% |
Insider · 30d
History →Bought
$152.14K
2 txns
Sold
$2.93M
8 txns
Net flow
−$2.78M
Aftermarket
LiveLast trade
$197.56
Bid
$192.69
2 sh
Ask
$202.00
1 sh
Spread
$9.310
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $2.48B | $319.5M | $2.15 |
| Q4 Dec 2025 | $2.28B | -$48.41M | $-0.33 |
| Q3 Sep 2025 | $2.45B | $466.5M | $3.17 |
| Q2 Jun 2025 | $2.65B | $634.8M | $4.35 |
| Q1 Mar 2025 | $2.43B | $240.5M | $1.64 |
| Q4 Dec 2024 | $2.45B | $266.7M | $1.83 |
Sector & industry today
LiveSectors
- Technology+2.51%
- Industrials+1.00%
- Basic Materials+0.65%
- Energy+0.59%
- Financial Services+0.23%
- Healthcare-0.18%
- Communication Services-0.18%
- Consumer Defensive-0.30%
- Consumer Cyclical-0.85%
- Real Estate-0.99%
- Utilities-1.03%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.19%
- Software - Services+9.60%
- Broadcasting+8.34%
- Medical - Equipment & Services+5.08%
- Computer Hardware+4.56%
- Financial - Mortgages+4.08%
- Staffing & Employment Services-3.62%
- Internet Content & Information+3.58%
- Coal-3.56%
- Oil & Gas Energy-3.54%
- Biotechnology+3.28%
- Electrical Equipment & Parts+3.27%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$211.42
+7.22% upside
Low
$143.00
Median
$214.00
High
$260.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIBglobenewswire.com·Jun 23, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIBglobenewswire.com·Jun 23, 2026
- Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipelinefeeds.benzinga.com·Jun 18, 2026
- Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyoutzacks.com·Jun 18, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIBprnewswire.com·Jun 18, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIBprnewswire.com·Jun 18, 2026
- Biogen to acquire RayThera for $1 billionreuters.com·Jun 17, 2026
- Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.globenewswire.com·Jun 17, 2026
Recent analyst activity
DB- Jun 22, 2026GradeOverweight → OverweightBiogen (BIIB) Reiterated at Overweight by Cantor Fitzgerald: Advancing with BIIB080Cantor Fitzgerald
- Jun 18, 2026GradeBuy → BuyNeedham Reiterates Buy Rating on Biogen (BIIB)Needham
- Jun 18, 2026PT$224.00Biogen price target raised to $224 from $206 at Morgan StanleyMorgan Stanley
- Jun 15, 2026PT$221.00Biogen price target lowered to $221 from $236 at MizuhoMizuho Securities
- Jun 08, 2026GradeBuy → BuyBiogen upgraded to Buy from Hold at NeedhamNeedham
- Jun 08, 2026PT$255.00Biogen upgraded to Buy from Hold at NeedhamNeedham
Financial scores
DBJun 23, 2026Altman Z
3.39
Safe
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
5/9
Average
≥ 7 strong · 4–6 average · < 4 weak
Peers
- TEVATeva Pharmaceutical Industries Limited$34.95$40.7B
- UTHRUnited Therapeutics Corporation$570.40$25B
- DXCMDexCom, Inc.$61.35$23.67B
- DGXQuest Diagnostics Incorporated$192.67$21.33B
- LHLabcorp Holdings Inc.$255.84$21.06B
- STESTERIS plc$214.40$21.04B
- INCYIncyte Corporation$96.91$19.36B
- WATWaters Corporation$307.12$18.28B
Total assets
$29.44B
Total debt
$6.95B
Cash & equiv
$3.01B
Operating CF
$2.2B
Free cash flow
$2.05B
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Murphy Nicole officer: Head of Pharm Ops and Tech | Buy | 3 | $585.11 | Feb 12, 2026 |
Singhal Priya officer: Head of Development | Sell | 2,660 | $531.55K | Feb 09, 2026 |
Singhal Priya officer: Head of Development | Sell | 748 | $134.12K | Feb 02, 2026 |
Singhal Priya officer: Head of Development | Sell | 517 | $69.05K | Sep 02, 2025 |
Izzar Rachid officer: Head of Global Product Strat. | Sell | 2,223 | $300.11K | Jul 08, 2025 |
Singhal Priya officer: Head of Development | Sell | 3,806 | $480.51K | May 19, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $9.81B | $1.88B | $1.29B | $8.83 | +13.18% |
| FY 2024 | $9.68B | $2.49B | $1.63B | $11.19 | +16.87% |
| FY 2023 | $9.84B | $2.1B | $1.16B | $7.97 | +11.81% |
| FY 2022 | $10.17B | $2.89B | $3.05B | $20.87 | +29.95% |
| FY 2021 | $10.98B | $2.79B | $1.56B | $10.40 | +14.17% |